167 related articles for article (PubMed ID: 12751480)
1. Atomoxetine for attention deficit/hyperactivity disorder.
Garces K
Issues Emerg Health Technol; 2003 May; (46):1-4. PubMed ID: 12751480
[TBL] [Abstract][Full Text] [Related]
2. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
Davids E; Gastpar M
Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatments for ADHD and the novel agent atomoxetine.
Bailey KP
J Psychosoc Nurs Ment Health Serv; 2003 Aug; 41(8):12-7. PubMed ID: 13677007
[No Abstract] [Full Text] [Related]
4. Atomoxetine (strattera) for ADHD.
Med Lett Drugs Ther; 2003 Feb; 45(1149):11-2. PubMed ID: 12571539
[No Abstract] [Full Text] [Related]
5. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
Wernicke JF; Kratochvil CJ
J Clin Psychiatry; 2002; 63 Suppl 12():50-5. PubMed ID: 12562062
[TBL] [Abstract][Full Text] [Related]
6. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
9. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.
Barton J
Arch Dis Child; 2005 Feb; 90 Suppl 1(Suppl 1):i26-9. PubMed ID: 15665154
[TBL] [Abstract][Full Text] [Related]
11. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
12. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.
Wernicke JF; Adler L; Spencer T; West SA; Allen AJ; Heiligenstein J; Milton D; Ruff D; Brown WJ; Kelsey D; Michelson D
J Clin Psychopharmacol; 2004 Feb; 24(1):30-5. PubMed ID: 14709944
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
Allen AJ; Kurlan RM; Gilbert DL; Coffey BJ; Linder SL; Lewis DW; Winner PK; Dunn DW; Dure LS; Sallee FR; Milton DR; Mintz MI; Ricardi RK; Erenberg G; Layton LL; Feldman PD; Kelsey DK; Spencer TJ
Neurology; 2005 Dec; 65(12):1941-9. PubMed ID: 16380617
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
[TBL] [Abstract][Full Text] [Related]
16. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
Biederman J; Gao H; Rogers AK; Spencer TJ
Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
[TBL] [Abstract][Full Text] [Related]
17. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.
Brown RT; Perwien A; Faries DE; Kratochvil CJ; Vaughan BS
Clin Pediatr (Phila); 2006 Nov; 45(9):819-27. PubMed ID: 17041169
[TBL] [Abstract][Full Text] [Related]
20. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]